OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
NEW YORK, April 26, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Solid Biosciences Inc. ("Solid Biosciences") (NASDAQ:SLDB) pursuant to the January 25, 2018 initial public offering and/or between January 25, 2018 and March 14, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Massachusetts. To get more information go to:
http://www.zlk.com/pslra-d/solid-biosciences-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Solid Bioscience’s lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) the company misled investors regarding the toxicity of SGT-001; and (3) consequently, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading.
If you suffered a loss in Solid Biosciences you have until May 29, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
